CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-07 | Sandrock Alfred Head of Research & Development | Sale | −7,672 | $440.00 | $3.4M | 10,169.11 |
| 2021-02-18 | Sandrock Alfred EVP, Research & Development | Grant or award · Restricted Stock Unit | +14,500 | 14,500 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −1,533 | $278.03 | $426K | 15,261.21 |
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise | +1,300 | 16,561.21 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise | +1,446 | 18,007.21 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise | +1,708 | 19,715.21 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −577 | $278.03 | $160K | 19,138.21 |
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −642 | $278.03 | $178K | 18,496.21 |
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −758 | $278.03 | $211K | 17,738.21 |
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise · Restricted Stock Unit | −1,300 | 1,466 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Other disposition · Restricted Stock Unit | −1,466 | 0 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise · Restricted Stock Unit | −1,446 | 5,442 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Other disposition · Restricted Stock Unit | −1,996 | 3,446 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Option exercise · Restricted Stock Unit | −1,708 | 10,352 | ||
| 2021-02-12 | Sandrock Alfred EVP, Research & Development | Other disposition · Restricted Stock Unit | −2,310 | 8,042 | ||
| 2021-01-27 | Sandrock Alfred EVP, Research & Development | Grant or award | +3,728 | 16,794.21 | ||
| 2020-11-04 | Sandrock Alfred EVP, Research & Development | Sale | −1,500 | $350.00 | $525K | 13,066.21 |
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Option exercise | +1,213 | 15,019.25 | ||
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −538 | $333.00 | $179K | 14,481.25 |
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Option exercise · Restricted Stock Unit | −1,213 | 915 |
Page 1 of 4 · 77 trades